Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells.

Leonova K, Safina A, Nesher E, Sandlesh P, Pratt R, Burkhart C, Lipchick B, Gitlin I, Frangou C, Koman I, Wang J, Kirsanov K, Yakubovskaya MG, Gudkov AV, Gurova K.

Elife. 2018 Feb 5;7. pii: e30842. doi: 10.7554/eLife.30842.

2.

Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.

Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, Gudkov AV, Plunkett RJ.

Neuro Oncol. 2017 Feb 1;19(2):186-196. doi: 10.1093/neuonc/now141.

3.

DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation.

Milutinovic S, Brown SE, Zhuang Q, Szyf M.

J Biol Chem. 2004 Jul 2;279(27):27915-27. Epub 2004 Apr 15.

4.

Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.

Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, Toshkov I, Purmal AA, Wang D, Liu S, Morrison C, Gudkov AV, Gurova KV.

Cancer Prev Res (Phila). 2012 Aug;5(8):1025-35. doi: 10.1158/1940-6207.CAPR-11-0529. Epub 2012 Jun 11.

6.

Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.

Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR.

J Biol Chem. 2003 May 23;278(21):18980-9. Epub 2003 Mar 20.

7.

Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines.

Ou JN, Torrisani J, Unterberger A, Provençal N, Shikimi K, Karimi M, Ekström TJ, Szyf M.

Biochem Pharmacol. 2007 May 1;73(9):1297-307. Epub 2007 Jan 5.

PMID:
17276411
9.

p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs.

Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov AV.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E89-98. doi: 10.1073/pnas.1216922110. Epub 2012 Dec 10.

10.
11.

Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling.

Kirsanov K, Fetisov T, Lesovaya EA, Maksimova V, Trukhanova L, Antoshina E, Gor'kova T, Morozova O, Safina A, Fleyshman D, Salimov R, Shipaeva E, Ivanov R, Leonov A, Purmal AA, Belitsky GA, Gudkov AV, Gurova KV, Yakubovskaya MG.

Cancer Prev Res (Phila). 2020 Jan;13(1):53-64. doi: 10.1158/1940-6207.CAPR-19-0198. Epub 2019 Oct 25.

PMID:
31653646
13.

Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1A.

Halaburková A, Jendželovský R, Kovaľ J, Herceg Z, Fedoročko P, Ghantous A.

Clin Epigenetics. 2017 Jun 8;9:62. doi: 10.1186/s13148-017-0359-x. eCollection 2017.

14.

Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins.

Chang HW, Valieva ME, Safina A, Chereji RV, Wang J, Kulaeva OI, Morozov AV, Kirpichnikov MP, Feofanov AV, Gurova KV, Studitsky VM.

Sci Adv. 2018 Nov 7;4(11):eaav2131. doi: 10.1126/sciadv.aav2131. eCollection 2018 Nov.

15.

Dynamic and selective nucleosome repositioning during endotoxin tolerance.

El Gazzar M, Liu T, Yoza BK, McCall CE.

J Biol Chem. 2010 Jan 8;285(2):1259-71. doi: 10.1074/jbc.M109.067330. Epub 2009 Nov 9.

16.
17.

Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.

Quivy V, De Walque S, Van Lint C.

Subcell Biochem. 2007;41:371-96. Review.

PMID:
17484137
18.
19.

Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.

Fass DM, Reis SA, Ghosh B, Hennig KM, Joseph NF, Zhao WN, Nieland TJ, Guan JS, Kuhnle CE, Tang W, Barker DD, Mazitschek R, Schreiber SL, Tsai LH, Haggarty SJ.

Neuropharmacology. 2013 Jan;64:81-96. doi: 10.1016/j.neuropharm.2012.06.043. Epub 2012 Jul 4.

20.

Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms.

Jin MZ, Xia BR, Xu Y, Jin WL.

Front Oncol. 2018 Dec 7;8:598. doi: 10.3389/fonc.2018.00598. eCollection 2018. Review.

Supplemental Content

Support Center